Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

TENET HEALTHCARE CORP (THC)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $291.54 (close 2026-11-16); latest close $263.19 (2026-11-20), -9.7% since the report; figures re-marked at the latest close

Conclusion: WATCH

Conviction low · base case +46% · downside -17% · upside +77%

THC is priced at 1.52x TTM EV/Sales, with the market treating the Q3 2026 Conifer transition benefit and the 2027 reimbursement and payer-mix warnings as permanent even though FY2026 guidance is $5.05-$5.20B Adjusted EBITDA and TTM free cash flow is $3.33B. The call is WATCH because the evidence cuts both ways: ROIC of 23.8% against a 7.0% WACC passes the quality test, but there is no durable moat and the headline run rate is inflated. The downside case is $218.11, -25.2%, on -1.5% sales at a compressed EV/Sales of 1.29x (today 1.52x). The base case is $383.67, +31.6%, on EV/Sales at 1.85x, the peer median EV/Sales. The upside case is $465.30, +59.6%, on a re-rating to 1.99x on the cited dated catalyst.

Key numbers

  • Share price: $263.19
  • Market cap: $20.95B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $22.15B
  • EV / EBITDA (TTM): 5.0x
  • P/E (TTM): 7.2x
  • FCF yield: 15.8%
  • Price / book: 3.85x
  • Earnings-quality flags (TTM): none flagged
  • P/E, operating (tax-normalized) (TTM): 6.0x
  • EV / FCF (TTM): 9.4x
  • Revenue growth (latest fiscal year): +3.1%
  • ROIC (TTM): 23.8%
  • WACC: 6.9%
  • Economic profit spread: +17.0 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Tenet makes money through two FY2025 segments: Hospital Operations (50 acute care and specialty hospitals, 132 outpatient facilities, plus Conifer revenue-cycle management) and Ambulatory Care (USPI interests in 533 ASCs and 26 surgical hospitals at Dec. 31, 2025). Since the FY2020 report, the company went from three segments including a planned Conifer spin-off to two segments and full Conifer ownership in January 2026, while cutting hospitals from 65 to 50 and licensed beds from 17,178 to 12,494. FY2025 revenue was $21.31B with $3.51B operating income and $1.41B net income to common; TTM to Sep. 2026 revenue was $22.15B with $5.40B operating income and $2.90B net income to common. Cash generation is large: $3.54B FY2025 operating cash flow and $4.24B TTM, with $1.39B FY2025 and $1.81B TTM buybacks reducing diluted shares to 83.08M TTM from 106.26M in FY2020.

  2. ✓ 2. Competitive advantage

    The filings describe no durable moat: THC competes market-by-market on quality, location, service breadth, reputation and physician relationships, and its physicians can move patients to rivals at any time. It states a structural disadvantage versus not-for-profit and government-owned facilities (endowments, tax-exempt financing, tax exemptions, discounted drug pricing) and heavy payer concentration — 70%, or $9.696 billion, of FY2025 Hospital Operations net patient service revenues came from managed care payers. What it does have is scale and cash generation: revenue $21.31B in FY2025 and $22.15B TTM to 2026-09-30, operating income $3.51B and $5.40B, operating cash flow $3.54B and $4.24B, funding $1.39B and $1.81B of buybacks. That is a scale-and-cash story in a price-competitive, low-switching-cost business, not a franchise.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 (quarter ended 2026-09-30) shows 6.5% revenue growth to $5,631M and Adjusted EBITDA of $1,355M (+23.3%, 24.1% margin), but $97M of the revenue and a $147M favorable net impact on Adjusted EBITDA came from the Conifer/CommonSpirit transition catch-up, not core operations; net income available to common was $1.000 billion ($12.41 diluted) versus $342M ($3.86), with adjusted diluted EPS of $6.64 versus $3.70. Volumes grew modestly (same-hospital admissions +2.8%, adjusted admissions +3.2%) while payer mix worsened — charity and uninsured admissions +26.0% and lower exchange admissions — and labor cost fell (salaries, wages and benefits 38.6% of revenue versus 41.7%). Cash was $2.674 billion at September 30, 2026, $255M went to buybacks in the quarter, and FY 2026 Adjusted EBITDA guidance was raised to $5.05–$5.20 billion. Risk factors were unchanged from the FY2025 10-K.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans